Cerevance Appoints David H. Margolin, MD, PhD as Senior Vice President of Clinical and Translational Medicine

BOSTON--(BUSINESS WIRE)-- Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has appointed David H. Margolin, M.D., Ph.D., as Senior Vice President of Clinical and Translational Medicine. Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period. There, he leveraged his expertise in designing and leading translational medicine initiatives as well as clinical trials from phase 1 to phase 4 across various neurologic and rare disease indications, spanning biologics, small molecules and cell and gene therapies. Notably, Dr. Margolin served as the medical lead for the development of Lemtrada (alemtuzumab) which is now marketed in over 60 countries.

A board-certified neurologist with additional expertise in cell and molecular immunology, Dr. Margolin obtained his bachelor’s degree from Harvard College magna cum laude and his M.D. and Ph.D. degrees from the University of Pennsylvania. He completed his residency at Massachusetts General Hospital, followed by a research fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. Dr. Margolin served on the faculty in neurology at Harvard Medical School for 15 years, has authored more than 30 publications in peer-reviewed journals including The Lancet, New England Journal of Medicine, Brain, Blood, and Neurology, and is an inventor on several patents.

“David brings a critical combination of skills to Cerevance, with a stellar track record leading clinical development as well as a deep knowledge of neuroscience,” noted Brad Margus, CEO of Cerevance. “He will ensure the thoughtful execution of our more advanced programs while concurrently helping us dive into our rich human brain tissue datasets to select new drug targets with which we can expand our pipeline.”

"Cerevance’s unique platform provides an opportunity to identify novel targets for neurological and psychiatric diseases on an unprecedented scale," said Dr. Margolin. “I look forward to joining Cerevance’s team, advisors and investors in pursuing their vision of creating innovative and highly effective treatments for the millions of people with these diseases."

About Cerevance

Cerevance is a recently formed pharmaceutical company focused on central nervous system diseases. The company’s strengths include a powerful technology platform, a pipeline of discovery-stage and clinical-stage compounds, a proven leadership team and more than $40 million of funding from Takeda Pharmaceuticals, Lightstone Ventures and the Dementia Discovery Fund managed by SV Life Sciences. The company believes it is well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171127005151/en/